Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience

Objectives: This paper aims to describe the clinical experience with Daratumumab (DARA), a first-in-class anti-CD38 human monoclonal IgG1κ antibody monotherapy, in severe patients with AL and biopsy-proven renal involvement. Immunoglobulin light chain (AL) amyloidosis with multi-organ involvement is...

Descripción completa

Detalles Bibliográficos
Autores principales: Roccatello, Dario, Fenoglio, Roberta, Naretto, Carla, Baldovino, Simone, Sciascia, Savino, Ferro, Michela, Rossi, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600836/
https://www.ncbi.nlm.nih.gov/pubmed/33050272
http://dx.doi.org/10.3390/jcm9103232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600836/
https://www.ncbi.nlm.nih.gov/pubmed/33050272
http://dx.doi.org/10.3390/jcm9103232

Ejemplares similares